$7.45
6.58%
Nasdaq, Jun 06, 10:15 pm CET
ISIN
US6700021040
Symbol
NVAX
Sector
Industry

Novavax, Inc. Stock price

$7.45
+1.38 22.73% 1M
-1.49 16.67% 6M
-0.59 7.34% YTD
-12.11 61.90% 1Y
-37.34 83.37% 5Y
-169.75 95.80% 10Y
-22.55 75.17% 20Y
Nasdaq, Closing price Fri, Jun 06 2025
+0.46 6.58%
ISIN
US6700021040
Symbol
NVAX
Sector
Industry

Key metrics

Market capitalization $1.21b
Enterprise Value $703.86m
P/E (TTM) P/E ratio 2.77
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.56
P/S ratio (TTM) P/S ratio 0.96
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 25.92%
Revenue (TTM) Revenue $1.25b
EBIT (operating result TTM) EBIT $422.82m
Free Cash Flow (TTM) Free Cash Flow $-196.61m
Cash position $731.48m
EPS (TTM) EPS $2.69
P/E forward 3.57
P/S forward 1.24
EV/Sales forward 0.72
Short interest 28.79%
Show more

Is Novavax, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,823 stocks worldwide.

Novavax, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Novavax, Inc. forecast:

4x Buy
57%
2x Hold
29%
1x Sell
14%

Analyst Opinions

7 Analysts have issued a Novavax, Inc. forecast:

Buy
57%
Hold
29%
Sell
14%

Financial data from Novavax, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1,255 1,255
26% 26%
100%
- Direct Costs 157 157
57% 57%
12%
1,098 1,098
75% 75%
88%
- Selling and Administrative Expenses 289 289
32% 32%
23%
- Research and Development Expense 387 387
33% 33%
31%
468 468
240% 240%
37%
- Depreciation and Amortization 45 45
1% 1%
4%
EBIT (Operating Income) EBIT 423 423
212% 212%
34%
Net Profit 479 479
220% 220%
38%

In millions USD.

Don't miss a Thing! We will send you all news about Novavax, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novavax, Inc. Stock News

Neutral
PRNewsWire
11 days ago
GAITHERSBURG, Md. , May 29, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference: Fireside Chat Date: Wednesday, June 4, 2025 Time: 2:00 – 2:30 p.m.
Negative
MarketBeat
17 days ago
Persistent volatility has plagued the S&P 500 for much of 2025, prompting widespread caution among many investors amid the uncertainties of trade battles, tariffs, domestic policy, and more. Investors might remember that many of the biggest rallies take place during these volatile periods, and there may be potential to win big gains for those with at least a moderate tolerance for risk.
Positive
Seeking Alpha
19 days ago
Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating their protein-based vaccine technology. The approval positions Novavax as the only non-mRNA COVID-19 vaccine with full FDA approval, offering a differentiated alternative amid growing mRNA fatigue. Sanofi partnership brings immediate cash, future royalties, and potential mile...
More Novavax, Inc. News

Company Profile

Novavax, Inc. is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm's vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Head office United States
CEO John Jacobs
Employees 952
Founded 1987
Website www.novavax.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today